Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Lifts Sales Outlook, Notes Key Approval Of Afib Device With Minnesota Ties is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific to stop heart device sales amid regulatory challenges
May 28 (Reuters) - Boston Scientific (BSX.N), opens new tab said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other ... Read More
Boston Scientific Ending Acurate Sales, Approval Efforts
Boston Scientific is throwing in the towel on its Acurate transcatheter aortic valve replacement, or TAVR, platform, citing rising costs of efforts to win regulatory approvals. Boston Scientific on ... Read More
Boston Scientific Lifts Annual Profit Forecast, Sees Smaller Tariff Impact
(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, banking on strong demand for its heart devices, and trimmed its expectation for tariff-related costs to half of the ... Read More
Boston Scientific to cut jobs after discontinuing heart device
Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that treat the heart failure-causing condition aortic stenosis, the medtech ... Read More
Boston Scientific pulls heart device from market
Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ... Read More
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Q2 revenue grew 22.8% to $5.06 billion, topping estimates of $4.89 billion; adjusted EPS came in at $0.75, beating $0.72 consensus. Cardiovascular sales rose 26.8%, while MedSurg gained 15.7%, led by ... Read More
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and ... Read More
Boston Scientific Ending Acurate Sales, Approval Efforts — Update
Boston Scientific is throwing in the towel on its Acurate transcatheter aortic valve replacement, or TAVR, platform, citing rising costs of efforts to win regulatory approvals. Boston Scientific on ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus